Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity.
Santollani L, Maiorino L, Zhang YJ, Palmeri JR, Stinson JA, Duhamel LR, Qureshi K, Suggs JR, Porth OT, Pinney W 3rd, Msari RA, Walsh AA, Wittrup KD, Irvine DJ. Santollani L, et al. Among authors: pinney w 3rd. Nat Immunol. 2024 Oct;25(10):1820-1829. doi: 10.1038/s41590-024-01925-7. Epub 2024 Aug 7. Nat Immunol. 2024. PMID: 39112631 Free PMC article.
Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity.
Santollani L, Zhang YJ, Maiorino L, Palmeri JR, Stinson JA, Duhamel LR, Qureshi K, Suggs JR, Porth OT, Pinney W 3rd, Msari RA, Wittrup KD, Irvine DJ. Santollani L, et al. Among authors: pinney w 3rd. bioRxiv [Preprint]. 2024 Jan 3:2024.01.03.573641. doi: 10.1101/2024.01.03.573641. bioRxiv. 2024. Update in: Nat Immunol. 2024 Oct;25(10):1820-1829. doi: 10.1038/s41590-024-01925-7 PMID: 38260254 Free PMC article. Updated. Preprint.
Tregs constrain CD8+ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy.
Palmeri JR, Lax BM, Peters JM, Duhamel L, Stinson JA, Santollani L, Lutz EA, Pinney W 3rd, Bryson BD, Wittrup KD. Palmeri JR, et al. Among authors: pinney w 3rd. bioRxiv [Preprint]. 2023 Feb 1:2023.01.30.526116. doi: 10.1101/2023.01.30.526116. bioRxiv. 2023. Update in: Nat Commun. 2024 Mar 1;15(1):1900. doi: 10.1038/s41467-024-45625-0 PMID: 36778460 Free PMC article. Updated. Preprint.
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
Pishesha N, Harmand TJ, Rothlauf PW, Praest P, Alexander RK, van den Doel R, Liebeskind MJ, Vakaki MA, McCaul N, Wijne C, Verhaar E, Pinney W 3rd, Heston H, Bloyet LM, Pontelli MC, Ilagan MXG, Jan Lebbink R, Buchser WJ, Wiertz EJHJ, Whelan SPJ, Ploegh HL. Pishesha N, et al. Among authors: pinney w 3rd. Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2116147118. doi: 10.1073/pnas.2116147118. Proc Natl Acad Sci U S A. 2021. PMID: 34654739 Free PMC article.
Induction of antigen-specific tolerance by nanobody-antigen adducts that target class-II major histocompatibility complexes.
Pishesha N, Harmand T, Smeding LY, Ma W, Ludwig LS, Janssen R, Islam A, Xie YJ, Fang T, McCaul N, Pinney W 3rd, Sugito HR, Rossotti MA, Gonzalez-Sapienza G, Ploegh HL. Pishesha N, et al. Among authors: pinney w 3rd. Nat Biomed Eng. 2021 Nov;5(11):1389-1401. doi: 10.1038/s41551-021-00738-5. Epub 2021 Jun 14. Nat Biomed Eng. 2021. PMID: 34127819